Clinical trials: Ventricular
Fabry Disease, Fabry Disease, Cardiac Variant
Fabry Disease in High-risk Patients With Left Ventricular Hypertrophy: Prevalence and Implementation of a Clinical Score
This study aims to evaluate the prevalence of Fabry Disease (FD) among a cohort of high risk patients with left ventricular hypertrophy (LVH) presenting at the University Hospital Würzburg over the last 20 years.
- Conditions
- Fabry Disease, Fabry Disease, Cardiac Variant, Lysosomal Storage Diseases, HCM - Hypertrophic Cardiomyopathy
- Trial name
- FAPREV-HCM (NCT04943991)
- Testing
- blood sampling (alpha-Galactosidase & LysoGb3)
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Wuerzburg University Hospital
Single-ventricle, Congenital Heart Disease
Fontan Imaging Biomarkers (FIB) Study
The goal of the Fontan Imaging Biomarkers (FIB) study is to identify the associations of blood and urine biomarkers to imaging parameters of ventricular mechanics.
- Trial name
- FIB (NCT03119090)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Boston Children's Hospital
Ischemic Heart Disease, Coronary Artery Disease
Controlled Trial of High-risk Coronary Intervention With Percutaneous Left Ventricular Unloading
Over 100,000 coronary stent procedures, where small balloons are used to stretch open a narrowed blood vessel, are performed every year in the United Kingdom to treat people who have conditions such as angina or have suffered a…
- Trial name
- CHIP-BCIS3 (NCT05003817)
- Testing
- Percutaneous left ventricular unloading
- Where
- United Kingdom
- Volunteers
- 300 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Paroxysmal Supraventricular Tachycardia
The NODE-202 Study (Study of Etripamil Nasal Spray in Pediatric Patients)
NODE-202 is a Phase 2, multicenter, multinational, single dose, open-label, 2-part, sequential design study in pediatric patients with an established diagnosis of paroxysmal supraventricular tachycardia (PSVT) presenting with a…
- Trial name
- NCT05763953
- Testing
- Etripamil NS
- Where
- 10 sites in United States, Canada and 2 more
- Volunteers
- 60 people
- Sponsor
- Milestone Pharmaceuticals Inc.
Congenital Heart Defects
Effects of High-intensity Interval Training on Exercise Capacity in Patients With Grown-up Congenital Heart Disease
Patients with congenital heart disease have long been discouraged from participating in physical exercise which has led to impaired exercise capacity in this population.
- Trial name
- HIIT-GUCH (NCT02632253)
- Testing
- HIIT, MICE
- Where
- Switzerland
- Volunteers
- 3 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Atrial Fibrillation (AF), Tachycardia
Evaluation of a Test Algorithm for Use to Analyze ECG Data Collected From a Test Device of a 24-hour Simulated Use Period
The purpose of this study is to demonstrate that the ZywieAI analysis algorithm can be used to analyze ECG data collected from ZywieZ3 devices with non-traditional lead placement over a 24-hour simulated use period by human…
- Conditions
- Atrial Fibrillation (AF), Tachycardia, Bradycardia, PVC - Premature Ventricular Contraction
- Trial name
- NCT07188129
- Testing
- Test Algorithm and Test Device
- Where
- United States
- Volunteers
- 153 people
- Sponsor
- Zywie, Inc.
Cardiogenic Shock Acute
Early Preventive Left Ventricle Unloading After VA-ECMO for Refractory Cardiogenic Shock
Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is increasingly being used worldwide to treat severe cardiogenic shock.
- Trial name
- EULODIA (NCT07027202)
- Testing
- Early Left Ventricle unloading
- Where
- 12 sites in France
- Volunteers
- 298 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Aortic Stenosis
A Comparison of Transcatheter Heart Valves in High Risk Patients With Severe Aortic Stenosis: The CHOICE Trial
A randomized controlled multicenter study comparing the acute hemodynamic performance of the Edwards Sapien XT and the Medtronic CoreValve transcatheter heart valves in high risk patients with severe symptomatic aortic stenosis.
- Trial name
- CHOICE (NCT01645202)
- Testing
- Transcatheter Aortic Valve Implantation (TAVI)
- Where
- Germany
- Volunteers
- 241 people
- Sponsor
- Segeberger Kliniken GmbH
STEMI - ST Elevation Myocardial Infarction (MI), Primary PCI - STEMI
Early Intracoronary N-Acetylcysteine During Primary PCI in STEMI: A Pilot Randomized Trial of Reperfusion Injury Biomarkers and Functional Recovery
Myocardial ischemia-reperfusion injury still poses a major therapeutic challenge in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI).
- Trial name
- NCT06850831
- Testing
- Antipac
- Where
- Indonesia
- Volunteers
- 110 people
- Sponsor
- dr. Ahmad Yasa, Sp.JP, Subsp.K.I.(K), M.Kes, FIHA, FasCC, FA
Lipoprotein Disorder, Arterial Stiffness
The Effect of Lipoprotein (a) on Arterial Stiffness, Endothelial Function and Myocardial Deformation
1. Introduction Lipoprotein(a), or Lp(a), is a type of lipoprotein that is structurally similar to LDL (low-density lipoprotein) but carries an additional protein called apolipoprotein (a). 2.
- Conditions
- Lipoprotein Disorder, Arterial Stiffness, Endothelial Dysfunction
- Trial name
- Lpa_endo (NCT07324902)
- Where
- 2 sites in Greece
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University of Athens
Aortic Valve Insufficiency, Aortic Valve Regurgitation
Trifecta™ Long Term Follow-Up (LTFU) Study
The Trifecta™ LTFU Study is a single-arm, multi-center, prospective, non-randomized, post-market study conducted in the United States and Canada to collect long-term safety and effectiveness data through 10 years after implant of…
- Conditions
- Aortic Valve Insufficiency, Aortic Valve Regurgitation, Aortic Valve Stenosis, Aortic Valve Incompetence
- Trial name
- NCT01593917
- Testing
- Trifecta™ Valve
- Where
- 11 sites in United States, Canada
- Volunteers
- 329 people
- Sponsor
- Abbott Medical Devices
Heart Failure
A Novel Automated & Comprehensive Approach for Ventricular Function Assessment in Heart Failure
Heart failure is a major health care burden. It can occur with either normal or reduced LV ejection fraction, depending on different degrees of ventricular remodelling.
- Trial name
- NCT02791126
- Testing
- Cardiovascular Magnetic Resonance, Echocardiogram
- Where
- Singapore
- Volunteers
- 78 people
- Sponsor
- National Heart Centre Singapore
Arrhythmia, Cardiovascular Diseases
Diagnostic Investigation of Sudden Cardiac Event Risk
The overall objective of the DISCERN study is to develop and validate a genomic diagnostic assay to identify patients at increased risk for lethal ventricular arrhythmias and sudden cardiac death (SCD).
- Conditions
- Arrhythmia, Cardiovascular Diseases, Heart Failure, CVD
- Trial name
- DISCERN (NCT00500708)
- Where
- 8 sites in United States
- Volunteers
- 1,564 people
- Sponsor
- CardioDx
Ventricular Fibrillation, Ventricular Tachycardia
Implantable Cardioverter Defibrillator (ICD) Support Groups and Veterans
In this study, we will compare the quality of life in veterans having ICD who attend the ICD support groups to those who do not.
- Conditions
- Ventricular Fibrillation, Ventricular Tachycardia, Sudden Cardiac Death
- Trial name
- NCT00846417
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Emory University
Heart Failure, Systolic, Iron Deficiencies
IV Iron and SGLT2 Inhibitor on Ventricular Function and Myocardial Iron Content in Heart Failure With Iron Deficiency
Background. Treatment with intravenous iron has been shown to improve symptoms, functional capacity, and quality of life in patients with heart failure with reduced ejection fraction (HFrEF) and iron deficiency.
- Trial name
- COMBINED-HF (NCT06434025)
- Testing
- Iron Carboxymaltose, Dapagliflozin 10mg Tab
- Where
- Brazil
- Volunteers
- 99 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Myocardial Infarct, Heart Failure
IMPACT-CABG Trial: IMPlantation of Autologous CD133+ sTem Cells in Patients Undergoing CABG
Following myocardial infarct, cellular therapy is a potential approach to repopulate the injured myocardium, to treat heart failure and restore cardiac function.
- Trial name
- IMPACT-CABG (NCT01033617)
- Testing
- Injection of stem cells at time of coronary artery bypass grafting
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Diabetes Type 2, Hyperglycaemia (Diabetic)
Effect of Hyperglycaemia and Moxifloxacin on QTc Interval in T2DM
Diabetes is a significant risk factor for sudden cardiac death, with the QTc interval on electrocardiograms (ECGs) often prolonged in diabetic patients due to factors such as hyperglycaemia and insulin resistance.
- Conditions
- Diabetes Type 2, Hyperglycaemia (Diabetic), QT Interval, Variation in, Torsades de Pointes
- Trial name
- NCT07014735
- Testing
- glucose, moxifloxacin
- Where
- United Kingdom
- Volunteers
- 14 people
- Sponsor
- Richmond Pharmacology Limited
Ventricular Dysfunction, Myocardial Infarction
Autologous Bone Marrow Transplanted Via Transendocardial Catheter to Chronic Myocardial Infarct Border Zone
The object of this open-labeled, uncontrolled pilot study was to investigate the safety and feasibility of percutaneously transplanting autologous bone marrow (ABM) cells into the myocardium using the helical needle…
- Trial name
- TABMMI (NCT00507468)
- Testing
- Transendocaridal Transplantation of Autologous Bone Marrow
- Where
- 2 sites in Argentina
- Volunteers
- 20 people
- Sponsor
- BioCardia, Inc.
Arrhythmias
Study Evaluating GAP-486 in Non-sustained Ventricular Tachycardia
To determine whether the administration of test article will decrease the occurrence of ventricular arrhythmias in patients who have acute coronary syndrome (unstable angina, ST segment elevated myocardial infarction or…
- Trial name
- NCT00124891
- Testing
- Double-blind investigational anti-arrhythmic, GAP-486
- Where
- 75 sites in United States, Brazil and 14 more
- Volunteers
- 500 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Left Ventricular Dysfunction, Heart Failure
INcrease Of VAgal TonE in CHF
The purpose of the INOVATE-HF study is to demonstrate the long-term safety and efficacy of vagus nerve stimulation with the CardioFit® system for the treatment of subjects with Heart Failure.
- Trial name
- INOVATE-HF (NCT01303718)
- Testing
- CardioFit® System, Standard of Care
- Where
- 87 sites in United States, Belgium and 6 more
- Volunteers
- 730 people
- Sponsor
- BioControl Medical
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.